Clinical Trial Search

Primary: Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48 — 83.3; 91.8; 85.4 percentage of participants

Primary: Patients With Complete Clearance of Actinic Keratosis (AKs) — 35; 6 Participants — p=<0.0001

Primary: Patients With Complete Clearance of Actinic Keratosis (AK) Lesions. — 50; 3 participants — p=0.001

Primary: Change in HbA1c From Baseline to Week 26 — -1.28; -1.48 percentage of total hemoglobin — p=0.002

Primary: Change From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Rocuronium or Succinylcholine — -0.06; 0.30 mmol/L — p=<0.0001

Primary: Percentage of Patients Experiencing Adverse Events — 73.1 percentage of patients

Primary: Proportion of Patients With Complete Clearance of Actinic Keratoses (AK) Lesions — 42; 5 participants — p=0.001

Primary: Time to Hemostasis (TTH) — 4.68; 4.38; 20.05 Minutes — p=<0.0001

Primary: Complete Clearance of Actinic Keratoses (AK) Lesions — 67; 7 participants — p=<0.001

Primary: Number of Subjects With Likelihood of Cirrhosis Based on "Hepatic Impairment Score" (HIS) — 146 Participants — p=0.0924

Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Statin…

Primary: Number of Subjects Reporting Grade 3 Symptoms (Solicited and Unsolicited). — 3; 1; 2 Participants

Primary: Change From Baseline in HAM-D17 Total Score at Week 8 or Final On-therapy (FOT) Evaluation — -8.68; -9.75; -10.5; -10.3 Units on a Scale — p=0.198

Primary: Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment — 586; 519; 471; 340 participants

Primary: Percentage of Subjects — 25.3; 2.8 percentage of subjects with complete cur — p=0.025